Recurrent severe diarrhea with acute kidney injury after drug reinitiation highlights a rare but serious enteropathy linked ...

Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.

A judge's ruling blocking the federal government's plan to change recommendations for routine childhood immunizations will ...

The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or obesity in a small study.

CytomX Therapeutics (NASDAQ:CTMX) outlined updated Phase 1 dose expansion results for its EpCAM-targeting Probody ...

Confirmed objective responses were observed at 8.6 and 10 mg/kg q3w, with a high overall disease control rate in late-line metastatic colorectal cancer. Progression-free survival estimates near 7 ...

A DR5-mediated apoptotic strategy combined with irinotecan/temozolomide achieved a 64.5% ORR and 87.1% DCR in ...

One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any drug currently on the market, underscoring its potential in the increasingly ...

Linerixibat targets pruritus pathobiology in PBC by blocking ileal bile acid reuptake, aiming to lower circulating pruritogenic bile acid–related mediators. GLISTEN demonstrated greater 24-week WI-NRS ...

The FDA has approved the first medication for cholestatic pruritus in adult patients with primary biliary cholangitis.The approval of linerixibat (Lynavoy, GSK) — an ileal bile acid transporter ...

L.A. County health officials are urging consumers not to eat Raw Farm-branded raw cheddar cheese after the product was linked ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...